Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children (PROMOTE-PEDS)

5 décembre 2018 mis à jour par: University of California, San Francisco

A Randomized Open Label Trial of HIV Protease Inhibitors for the Prevention of Malaria in HIV-Infected Children

HIV and malaria are major causes of morbidity and mortality in Sub-Saharan Africa and children bear the greatest brunt of both diseases. No single existing intervention is likely to control malaria in Africa. Rather, improvements in malaria prevention are likely to come from strategies that employ multiple proven interventions targeting different populations. HIV-infected children represent one of the most vulnerable subpopulations in these countries. It is possible that the use of protease inhibitor (PI) - based antiretroviral therapy (ART) in HIV-infected children living in areas of high malaria transmission could prevent malaria in this vulnerable population. An effective remedy that offers the possibility to further reduce malaria risk, such as PIs, is highly desirable. This study will determine whether a PI based ART regimen will reduce malaria among children living in a malaria endemic area of Uganda and receiving insecticide-treated bed nets (ITN) and TS. This study will compare two different ART regimens. Children enrolled in the study will start or continue to receive either standard Ugandan first line treatment ART regimen (NNRTI+2 NRTIs) or an ART regimen containing the HIV protease inhibitor (lopinavir/ritonavir +2 NRTIs) and followed for a period of 24 months.

Aperçu de l'étude

Statut

Complété

Les conditions

Intervention / Traitement

Description détaillée

This is an open label, single site, randomized clinical trial comparing PI-based ART to NNRTI-based ART for the prevention of malaria in HIV-infected children. The two ART drug regimens that will be used include: Treatment arm 1. LPV/r + 2 NRTIs and Treatment arm 2. NVP or EFV + 2 NRTIs. The study is designed to test the hypothesis that children receiving a PI-based ART regimen will have lower the incidence of malaria compared to children receiving an NNRTI- based ART regimen. The primary study endpoint of the study is malaria incidence.

The study site will be the Tororo District Hospital campus situated in Eastern Uganda, an area of high malaria transmission. Using convenience sampling, 300 HIV-infected children identified from the Tororo community aged 2 months to <11 years either eligible for ART-initiation or already receiving a first line ART regimen with HIV RNA<400 copies/ml will be evaluated for enrollment.

Eligible children will be randomized at enrollment to receive either a PI- based or an NNRTI-based ART regimen. At enrollment, all study participants will receive a long lasting ITN as part of a basic care package including a safe water vessel and multivitamins and given TS chemoprophylaxis, as per current standard of care for HIV-infected children in Uganda. On the day of ART initiation, patients will be counseled about the importance of adherence to ART and possible ART related toxicities. After 2 weeks, patients will be seen to assess adherence and toxicity to study medications by interview and clinical examination. Apart from this visit at week 2, patients will be seen at 4 week intervals timed from ART-initiation. Assessment of adherence will also be done for TS prophylaxis, ITN use and ART. Assessment of adherence to ART will be done by self report of missed doses and pill counts.

Participants will receive all routine and acute medical care at a designated study clinic open 7 days a week from 8 a.m. to 5 p.m. Parents/guardians will be asked to bring their child to the study clinic for all medical care. If after hours, they will be instructed to bring them to Tororo District Hospital premises (where the study clinic is located) and request that the study physician on-call be contacted. They will be followed for at least 24 months and up to 3 years. They will be seen monthly for routine assessments with laboratory evaluations done at every 3 months. At these visits, the study protocol will be reinforced with discussion regarding the need to come to the study clinic promptly upon the onset of any illness and to avoid use of outside medications. Study participants will also be followed closely for adverse events potentially due to study drugs and for malaria and HIV treatment outcomes. During the follow-up period, all patients presenting to the clinic with a new episode of fever will undergo standard evaluation (history, physical examination) and Giemsa-stained blood smear for the diagnosis of malaria.

Type d'étude

Interventionnel

Inscription (Réel)

176

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

  • Ouganda
      • Tororo, Ouganda
        • IDRC - Tororo Research Clinic

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

2 mois à 10 ans (Enfant)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion criteria:

  1. Age 2 months to < 11 years
  2. Confirmed HIV diagnosis. i. Children > 18 months: Documentation of HIV status must come from two assays. Assays include DNA PCR, HIV RNA, Western blot, or rapid HIV antibody test ii. Children < 18 months: Documentation will be DNA PCR confirmation only along with documentation of testing from the referral entity
  3. ART-naïve patients eligible for ART initiation per WHO/Uganda guidelines (see Table 1) or Patients receiving first line ART regimen with NNRTI +2 NRTI with at least one HIV RNA <400 copies/ml within the past 6 months
  4. Agreement to come to the study clinic for any febrile episode or other illness
  5. Agreement to avoid medications administered outside study protocol
  6. Provision of informed consent by parent/guardian and agreement to have child's care at the clinical site
  7. Lives within 50 km of study site

Exclusion criteria:

  1. ART-naïve children: children or their mothers that have received any dose of Nevirapine in the past 24 months
  2. Active medical problem requiring in-patient evaluation at the time of screening or enrollment
  3. History of cardiac conduction disorder or known significant cardiac structural defect
  4. Children receiving any disallowed medications (see section 4.3)

  5. Moderate, Severe or Life-threatening (Grade 2, 3, or 4) AST or ALT found within 4 weeks prior to enrollment:

    • AST: >113U/L (>2.5xULN)
    • ALT: >113U/L (>2.5xULN)

  6. Life-threatening (Grade 4) screening laboratory value found within 4 weeks prior to enrollment for the following:

    • Absolute neutrophil count: <500 mm3
    • Hemoglobin: <6.5 g/dL
    • Creatinine: >3.5xULN
    • Platelets: <25,000/mm3

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: La prévention
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Lopinavir/ritonavir (LPV/r) +2 NRTI
Lopinavir/ritonavir (LPV/r) +2 nucleoside reverse transcriptase inhibitor (NRTI)
Médicament: Lopinavir/Ritonavir (LPV/r)
Autres noms:
  • Aluvia
Médicament: 2 nucleoside reverse transcriptase inhibitor (NRTI)
The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin < 8 gm/dL, in which case it will be Abacavir. Stavudine will be used in the event that a participant is unable to take Abacavir for safety or other reasons.
Comparateur actif: Nevirapine (NVP) or Efavirenz (EFV) +2 NRTI
Nevirapine (NVP) or Efavirenz (EFV) +2 nucleoside reverse transcriptase inhibitor (NRTI)
Médicament: 2 nucleoside reverse transcriptase inhibitor (NRTI)
The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin < 8 gm/dL, in which case it will be Abacavir. Stavudine will be used in the event that a participant is unable to take Abacavir for safety or other reasons.
Médicament: Nevirapine (NVP)
NVP will be used for children < 3 years of age
Médicament: Efavirenz (EFV)
EFV for children ≥3 years of age

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Délai
Incidence-density of Malaria Defined as the Number of Incident Episodes of Malaria Per Time at Risk.
Délai: Time from randomization to at least 24 months of follow up or until end of the study
Time from randomization to at least 24 months of follow up or until end of the study

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Percentage of Uncomplicated Malaria Episodes With Accompanying Adverse Events That Occurred in the 28 Days Following Antimalarial Therapy
Délai: 28 days after antimalarial therapy
The rates of adverse events, defined as severity grade 2 or higher that are possibly, probably or definitely related to study drugs over the course of the 28-day period after antimalarial therapy with artemether-lumefantrine (AL).
28 days after antimalarial therapy
Incidence-density of Malaria Defined as the Number of Incident Episodes of Complicated Malaria Per Time at Risk.
Délai: Time from randomization to at least 24 months of follow up or until end of the study
Time from randomization to at least 24 months of follow up or until end of the study
Estimates of the 6-month Risk of a First Episode of Malaria
Délai: Enrollment to 6 months follow up
To assess the effect of ART independently of potential interactions with antimalarial therapy after treatment for malaria, we compared the two groups with respect to the time to the first episode of malaria. Cumulative risk was estimated using the Kaplan-Meier product-limit formula.
Enrollment to 6 months follow up
28-day Risk of Recurrent Parasitemia
Délai: 28 days after antimalarial therapy
To assess the effect of potential interactions between ART and artemether-lumefantrine, the risks of recurrent parasitemia at 28 days were compared between the two groups.
28 days after antimalarial therapy
63-day Risk of Recurrent Malaria
Délai: 28 days after antimalarial therapy
To assess the effect of potential interactions between ART and artemether-lumefantrine, the risks of recurrent malaria at 63 days were compared between the two groups.
28 days after antimalarial therapy

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

University of California, San Francisco

Collaborateurs

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Les enquêteurs

  • Chercheur principal: Grant Dorsey, MD, PhD, University of California, San Francisco
  • Directeur d'études: Diane V Havlir, MD, University of California, San Francisco
  • Chercheur principal: Moses R Kamya MBChB, MMed, MPH, Makerere University
  • Chercheur principal: Ted Ruel, MD, University of California, San Francisco
  • Chercheur principal: Jane Achan, MBChB, MPed, Makerere University

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 septembre 2009

Achèvement primaire (Réel)

1 janvier 2013

Achèvement de l'étude (Réel)

1 janvier 2013

Dates d'inscription aux études

Première soumission

14 septembre 2009

Première soumission répondant aux critères de contrôle qualité

15 septembre 2009

Première publication (Estimation)

16 septembre 2009

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

28 décembre 2018

Dernière mise à jour soumise répondant aux critères de contrôle qualité

5 décembre 2018

Dernière vérification

1 décembre 2018

Plus d'information

Termes liés à cette étude

Mots clés

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • H5747-34097
  • NIH PO1 HD059454
  • 2009-114 (Autre identifiant: Makerere Univ Fac of Med Research and Ethics Committee)
  • HS-620 (Autre identifiant: Uganda National Council for Science and Tech)
  • 551/ESR/NDA/DID-08/09 (Autre identifiant: Uganda National Drug Authority)
  • H5741-34097 and 10-00991 (Autre identifiant: UCSF Committee on Human Research)

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

Essais cliniques sur Infections à VIH

Essais cliniques sur Lopinavir/Ritonavir (LPV/r)

Rechercher des essais similaires

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

CROs by country

CROs in Liberia

Conditions

Maladies rares

Interventions en matière de drogue

Compléments alimentaires

Commanditaire / collaborateurs

Emplacements

3
S'abonner